Management of the PDA in preterm infants remains a contentious topic despite randomised controlled trial (RCT) evidence to date failing to demonstrate any clinically meaningful benefit with early pharmacotherapy.1, 2 Controversy exists on whether existing RCT evidence on PDA pharmacotherapy can be applied to micropreemies born at the limits of viability (22–24 weeks gestation) given the lack of representation of this population in contemporary RCTs. Giesinger et al, in their single-centre...
